Retrospective Multicenter Study in Non Small Cell Lung Cancer (nsclc) Patients with Epidermal Growth Factor Receptor (egfr) Activating Mutation Treated First-Line Tyrosine Kinase Inhibitor (tki): Evaluation of Progression According to Recist, Therapeutic Approach and Its Effect

Aim: Background: EGFR-TKI are a standard treatment for patients (pts) with NSCLC harboring activating EGFR mutations. All pts develop acquired resistance. At progression, the standard treatment is chemotherapy. Retrospective studies suggest that continuous use of EGFR-TKI beyond progressive disease (PD) may benefit some pts. Objective: The purpose of our retrospective multicentric study is to determine the frequency of continuation of EGFR-TKIs beyond RECIST-PD, and investigate the association of pts and disease characteristics with continuation of EGFR-TKIs at progression.